c-MET Oncogene in Renal Cell Carcinomas

Erlmeier F, Weichert W, Autenrieth M, Ivanyi P, Hartmann A, Steffens S (2016)

Publication Type: Journal article

Publication year: 2016

Journal

Aktuelle Urologie Georg Thieme Verlag

Book Volume: 47

Pages Range: 475-479

Journal Issue: 6

DOI: 10.1055/s-0042-115401

Abstract

c-Met plays a significant role in multiple cellular processes. Being encoded by a proto-oncogene, tyrosine kinase supports aggressive tumour behaviour such as tumour invasiveness and formation of metastases. For some subtypes of renal cell carcinoma studies have shown a association between c-Met expression and clinical outcome or prognosis. Therefore, c-Met represents a prognostic marker in renal cell carcinoma.Furthermore, c-MET will play a decisive role as a possible target for targeted therapies in the era of personalised medicine. Especially for RCC, the dual inhibition of VEGF and c-MET tyrosine kinase in cases of metastatic, treatment-resistant tumours is gaining clinical relevance. The role of c-Met has not been fully elucidated for all subtypes of renal cell carcinomas. The relevance of c-Met for the remaining subtypes of renal tumours has yet to be clarified.

Authors with CRIS profile

Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie

Involved external institutions

Universitätsklinikum Münster DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) Technische Universität München (TUM) DE Germany (DE)

How to cite

APA:

Erlmeier, F., Weichert, W., Autenrieth, M., Ivanyi, P., Hartmann, A., & Steffens, S. (2016). c-MET Oncogene in Renal Cell Carcinomas. Aktuelle Urologie, 47(6), 475-479. https://doi.org/10.1055/s-0042-115401

MLA:

Erlmeier, F., et al. "c-MET Oncogene in Renal Cell Carcinomas." Aktuelle Urologie 47.6 (2016): 475-479.

BibTeX: Download